ReviewJournal of immunology research2015
Progress and challenges toward the development of vaccines against avian infectious bronchitis.
Review in Journal of immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it, 164 citations in OpenAlex.
- The Reassessed Potential of SARS-CoV-2 Attenuation for COVID-19 Vaccine Development-A Systematic Review.Viruses · 2022Pooled it
- A Novel Effective Nanoadjuvant System for Poultry Vaccines.Vaccines · 2026Article
- Accumulation of mutations in nsp4, E, and the S2 subunit underlies mammalian cell tropism expansion and virulence attenuation of avian coronavirus.PLoS pathogens · 2026Article
- Evaluation of the Serological Baseline Values of Broiler Chickens Jointly Vaccinated with Infectious Bronchitis H + 120 and GI-13 Preparations Under Field Conditions.Animals : an open access journal from MDPI · 2026Article
- Immunoinformatics-driven design of a conserved RNA-dependent RNA polymerase-based multi-epitope vaccine against avian infectious bronchitis virus.Veterinary world · 2026Article
- Article
- Duckweed-based edible vaccine confers complete protection against avian infectious bronchitis virus by inducing robust mucosal and systemic immunity.Plant biotechnology journal · 2025Article
- Infectious Bronchitis Virus Activates the Aryl Hydrocarbon Receptor During In Vitro Infection.Veterinary sciences · 2025Article
- Design and development of a novel multi-epitope DNA vaccine candidate against infectious bronchitis virus: an immunoinformatic approach.Archives of microbiology · 2025Article
- Article
- Infectious Bronchitis Virus (IBV) in Vaccinated and Non-Vaccinated Broilers in Brazil: Surveillance and Persistence of Vaccine Viruses.Microorganisms · 2025Article
- Article
- Evaluation of the efficacy of commercial live vaccines against the local Thai QX field strain for the protection of specific pathogen-free chicks.Veterinary world · 2024Article
- Article
- Clinical, pathological, and genotypic analysis of infectious bronchitis virus in broiler chickens in the Abu Dhabi Emirate, United Arab Emirates.Frontiers in veterinary science · 2024Article
- Avian infectious bronchitis virus (AIBV) review by continent.Frontiers in cellular and infection microbiology · 2024Review
- One-pot Golden Gate Assembly of an avian infectious bronchitis virus reverse genetics system.PloS one · 2024Article
- Article
- Development and Immunoprotection of Bacterium-like Particle Vaccine against Infectious Bronchitis in Chickens.Vaccines · 2023Article
- Antigenic Characterization of Infectious Bronchitis Virus in the South China during 2021-2022.Viruses · 2023Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Avian infectious bronchitis (IB) is a widely distributed poultry disease that has huge economic impact on poultry industry. The continuous emergence of new IBV genotypes and lack of cross protection among different IBV genotypes have been an important challenge. Although live attenuated IB vaccines remarkably induce potent immune response, the potential risk of reversion to virulence, neutralization by the maternal antibodies, and recombination and mutation events are important concern on their usage. On the other hand, inactivated vaccines induce a weaker immune response and may require multiple dosing and/or the use of adjuvants that probably have potential safety risks and increased economic burdens. Consequently, alternative IB vaccines are widely sought. Recent advances in recombinant DNA technology have resulted in experimental IB vaccines that show promise in antibody and T-cells responses, comparable to live attenuated vaccines. Recombinant DNA vaccines have also been enhanced to target multiple serotypes and their efficacy has been improved using delivery vectors, nanoadjuvants, and in ovo vaccination approaches. Although most recombinant IB DNA vaccines are yet to be licensed, it is expected that these types of vaccines may hold sway as future vaccines for inducing a cross protection against multiple IBV serotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.